Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
NCT ID: NCT00052169
Last Updated: 2007-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
33 participants
INTERVENTIONAL
2003-01-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Overexpresssion of EGFR and/or TGF-alpha is frequent in human breast cancer and has been correlated in many cases with poor prognostic features. Inhibition of the EGFR pathway has been proposed as a potential therapeutic modality in advanced breast cancer. The antiproliferative activity of ZD 1839 in combination with cytotoxic drugs, such as docetaxel was evaluated in breast cancer cell lines ZR-75-1 and MCF-10A ras that coexpress EGFR and TGF-alpha. Combination treatment demonstrated dose dependent supra-additive growth inhibition and markedly enhanced apoptotic cell death.
Although taxanes bind to the microtubular network in cells that is essential for mitotic and interphase cellular functions, the mechanism by which these agents induce cell death is not entirely clear. Docetaxel has also shown dose-dependent anti-angiogenic activity. Thus, the mechanism(s) of anti-tumor activity of docetaxel remain unclear and combinations of signal transduction pathway inhibition and/or anti-angiogenesis may provide potentiation of concurrent ZD 1839 and docetaxel therapy.
This phase 2 trial is designed to prospectively investigate the efficacy and safetey of combination therapy with ZD 1839 and docetaxel in patients with metastatic breast cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZD1839 in combination with docetaxel
Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed consent
* Current diagnosis of metastatic breast cancer
* At least one uni-dimensionally measurable lesion with clearly defined margins
* Patients taking bisphosphonates for documented prior bone metastasis may be included
* Patients may have received prior adjuvant chemotherapy including an anthracycline and/or an alkylating agent. Patients may have received prior paclitaxel or trastuzumab for adjuvant therapy. Patients may not have received prior docetaxel treatment
* Patients may have received unlimited prior hormonal therapy regimens for metastatic disease or adjuvant therapy and must have documentation of progressive disease prior to entry. Hormonal therapy must be discontinued at least 2 weeks prior to study entry
* Patients may have received prior radiation therapy provided it was completed at least 2 weeks before study entry. Prior radiotherapy to treat bone metastasis or spinal cord compression is permitted provided it was completed prior to study entry
* Zubrod performance status 0, 1, or 2
* Life expectancy of 12 weeks or more in opinion of investigator
* LVEF greater than or equal to LLN without clinical signs or symptoms of heart failure
* adequate bone marrow, hepatic, and renal function
Ineligibility Criteria
* Prior ZD1839 or other anti EGFR or small molecule TKI
* Previous or concurrent chemo or Herceptin for metastatic breast cancer
* Unresolved non-permanent major end organ chronic toxicity from previous anticancer therapy greater than CTC grade 2
* Radiation therapy less than 14 days before study entry, with exception of RT to treat bone metastasis or spinal cord compression
* Incomplete healing of surgical incision from previous major surgery
* Newly diagnosed (within 12 weeks) intracerebral metastases
* Signs of neurological symptoms consistent with new onset spinal cord compression
* Evidence of severe or uncontrolled systemic disease
* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for patient to participate
* Pregnancy or breast feeding
* Patients who are currently using contact lenses. Patients who discontinue wearing contact lenses prior to study entry are eligible.
* Patients with untreated ocular inflammation or infection
* Patients with contraindications to corticosteroid use
* History of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer
* Patients receiving other investigational drugs
* Previous docetaxel treatment
* Patients currently taking systemic retinoids or herbal medicines
* Patients currently taking drugs known to induce Cyt P4503A4
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
NSABP Foundation Inc
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NSABP Foundation, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norman Wolmark, MD
Role: PRINCIPAL_INVESTIGATOR
NSABP Foundation Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NSABP Operations Center
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dennison SK, Jacobs SA, Wilson JW, Seeger J, Cescon TP, Raymond JM, Geyer CE, Wolmark N, Swain SM. A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs. 2007 Dec;25(6):545-51. doi: 10.1007/s10637-007-9055-6. Epub 2007 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSABP FB-IR-002
Identifier Type: -
Identifier Source: org_study_id